Merck has completed its previously announced $3.4bn acquisition of SpringWorks Therapeutics, a biopharmaceutical company based in Stamford, Connecticut.

The closing of the transaction follows the receipt of necessary regulatory approvals and standard closing conditions. The deal was announced in April 2025.

According to Merck, the integration is expected to immediately bolster its revenue and enhance its earnings per share pre (EPS pre) by 2027.

SpringWorks brings to Merck a portfolio that includes therapies for rare tumours where treatment options are limited. These include OGSIVEO (nirogacestat), approved by the US Food and Drug Administration (FDA) for adult patients with progressing desmoid tumours.

Last month, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending its approval.

SpringWorks also offers GOMEKLI (mirdametinib), the sole FDA-approved treatment for both adult and paediatric patients aged two and over with neurofibromatosis type 1-associated plexiform neurofibromas. CHMP endorsed its approval in May 2025.

The acquisition aligns with Merck’s strategic objectives to expand its presence in the US and strengthen its healthcare division through targeted acquisitions and in-licensing innovative compounds at various development stages.

This move also enables SpringWorks to leverage Merck’s global resources to enter markets outside the US.

Merck CEO Belén Garijo said: “The acquisition of SpringWorks illustrates our decisive portfolio approach to further position Merck as a globally diversified science and technology powerhouse.

“This is the largest acquisition we have made for our Healthcare business sector in nearly 20 years, marking an exciting new chapter for Healthcare.

“Furthermore, we remain committed to identifying merger and acquisition (M&A) opportunities across our three business sectors, with a focus on Life Science, prioritising strategic fit, financial robustness, and long-term value creation.”

Alongside SpringWorks’ offerings, Merck holds worldwide rights to pimicotinib, an investigational therapy for tenosynovial giant cell tumour being developed with Abbisko Therapeutics with regulatory filings underway. The combined portfolios aim to meet the needs of patients with rare tumours who face significant treatment gaps.

Following this acquisition, SpringWorks’ shares will cease trading on Nasdaq, as Merck assumes full ownership. Shareholders in SpringWorks are receiving $47 per share in cash.